Covid-19 Vaccine: Aurobindo Expects Phase-I, II Trials By End Of 2020
Aurobindo Pharma has said it is expecting its proposed vaccine candidate for Covid-19 to undergo phase-1 and 2 trials by the end of 2020, while Phase III may be undertaken during March-April next year.
Managing Director Narayanan Govindarajan in the recently held earnings call with analysts said the city-based pharma major had earmarked $150-200 million towards capital expenditure during the current fiscal year.
He said the vaccine for Covid-19 was being developed by Profectus BioSciences in the US, which was acquired by Aurobindo Pharma’s subsidiary Auro Vaccines LLC.
According to Govindarajan, the company's viral vaccine manufacturing capacity in India would be undertaken in two phases.
Coutts Sets Scope On New Continent
Coutts steps into private marketsCoutts, the private bank best known for serving Britain’s wealthiest families and the... Read more
From Cypherpunk To Citadel
How Crypto Moved from the Wild West to the Mainstream Financial SystemA long-form analysis of Bitcoin's journey from fri... Read more
ACB Securities: Building Scale, Trust & Innovation
ACB Securities: Building Scale, Trust and Innovation in Vietnam’s Capital MarketsACB Securities (ACBS) is emerging as ... Read more
War Risk Returns To Markets As VIX Surges
For most of the past year, global markets behaved as though geopolitical risk had largely disappeared. Inflation was eas... Read more
Stablecoin The Future Of Currency?
The payments system is undergoing a quiet but consequential shift. What was once the exclusive preserve of central banks... Read more
BoE Loosens Capital Rules
The Bank of England has taken a significant step towards easing post-crisis regulation by lowering its estimate of the c... Read more